StockNews.com Upgrades InfuSystem (NYSE:INFU) to “Strong-Buy”

StockNews.com upgraded shares of InfuSystem (NYSE:INFU) from a buy rating to a strong-buy rating in a research note published on Friday morning.

InfuSystem Price Performance

Shares of NYSE INFU opened at $5.97 on Friday. The firm has a market cap of $127.13 million, a price-to-earnings ratio of -597,000.00 and a beta of 1.46. InfuSystem has a 52-week low of $5.74 and a 52-week high of $10.99. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.07 and a quick ratio of 1.64.

InfuSystem (NYSE:INFU) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The business had revenue of $33.70 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Kings Path Partners LLC acquired a new stake in InfuSystem in the second quarter worth about $514,000. First Eagle Investment Management LLC grew its position in shares of InfuSystem by 12.7% during the 1st quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company’s stock worth $5,187,000 after buying an additional 68,021 shares during the period. Sequoia Financial Advisors LLC acquired a new position in shares of InfuSystem during the 2nd quarter worth about $272,000. Squarepoint Ops LLC acquired a new position in shares of InfuSystem during the 2nd quarter worth about $230,000. Finally, Ranger Investment Management L.P. grew its position in shares of InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock worth $7,271,000 after buying an additional 30,835 shares during the period. 71.13% of the stock is owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.